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a b s t r a c t
Background/Objectives: Infection with varicella zoster virus (VZV) produces lifelong immunity, but dura-
tion of post-vaccination immunity has not been established. The purpose of this study is to determine if a
difference exists in the long-term seropositivity of anti-VZV antibodies in a cohort of young adults who
were vaccinated against varicella as compared to a similar cohort with a history of chickenpox disease,
and to determine which variables best predict waning seropositivity following varicella vaccination.
Methods: This retrospective cohort study captures immunization and serology data from approximately
10,000 recruits who entered basic military training between January 1, 2008, and December 31, 2015, and
who have childhood immunization records in the Air Force Aeromedical Services Information
Management System. Varicella vaccine immunogenicity was determined relative to the immunogenicity
of chickenpox disease, as measured by multiplex flow immunoassay. Among vaccine recipients, waning
seroimmunity was modeled and adjusted for several important covariates.
Results: Basic military trainees who received varicella vaccine in childhood were 24% less likely to be
seropositive to VZV than trainees who were exempt from vaccine due to a history of chickenpox disease.
There was no significant difference in seropositivity between male and female trainees. The odds of a vac-
cinated trainee being seropositive to VZV decreased by 8% with each year elapsed since vaccination.
Seroprevalence declined below estimated herd immunity thresholds in vaccinated trainees born after
1994, and in the cohort as a whole for trainees born after 1995.
Conclusion: Despite prior vaccination, seroimmunity in a large cohort of young adults unexposed to wild-
type VZV failed to meet the estimated threshold for herd immunity. If vaccination in accordance with the
current US VZV vaccination schedule is inadequate to maintain herd immunity, young adults not previ-
ously exposed to wild-type VZV may be at increased risk for varicella outbreaks.
Published by Elsevier Ltd.
1. Background
Varicella vaccine was first licensed in the United States in 1995,
and the Advisory Committee on Immunization Practices (ACIP)
published its initial recommendations in 1996, advising one vac-
cine dose to susceptible children under 12 years of age [1]. The
incidence of varicella decreased by 90% over the next 10 years,
from approximately 4 million yearly cases seen before the vaccine
was available [2,3]. However, varicella outbreaks continued to
occur in populations of highly-vaccinated schoolchildren, and ACIP
recommended a second dose of varicella vaccine in 2006 [4]. By
2012, two-dose varicella vaccination coverage levels approached
the two-dose coverage levels of 82–94% seen for measles, mumps,
and rubella (MMR), and wider adoption of two-dose varicella vac-
cination requirements for school entry have been instrumental in
progression toward the Healthy People 2020 (HP2020) target of
95% of kindergarten children receiving two doses of varicella vac-
cine [5]. Despite this progress, estimated 2015 two-dose varicella
vaccination coverage of 84.6% for adolescents aged 13–15 falls
below the HP2020 target of 90% [6].
As the increased utilization of the varicella vaccine leads to
reductions in circulating wild-type varicella-zoster virus (VZV),
inadequately immunized children may acquire infection at an
older age when they are at increased risk for severe infection [7].
This can be prevented by targeted vaccination of susceptible
adolescents. ACIP criteria for evidence of immunity to varicella
include documentation of age-appropriate vaccination, laboratory
http://dx.doi.org/10.1016/j.vaccine.2017.03.054
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evidence of immunity, birth in the United States before 1980, or
verification of a history of varicella disease (i.e., chickenpox) by a
healthcare provider [4]. As verified by serologic surveys, confirma-
tion of disease through either medical record review or patient/-
parent recall of disease has high sensitivity and positive
predictive value in unvaccinated adolescents [8,9]. Seroconversion
estimates following varicella vaccination are approximately 60–
70% after one dose and 88% after two doses [9,10]. Despite a ran-
domized controlled trial demonstrating one-dose vaccine efficacy
of 94% and two-dose efficacy of 98% after 10 years [11], varicella
outbreaks in immunized children with attack rates of 10–13% sug-
gest varicella vaccine effectiveness of 82–85% among one-dose
recipients and 86–88% among two-dose recipients [12–14]. In a
nationwide retrospective study in Taiwan, annual breakthrough
infections of chickenpox of up to 2% were seen among persons vac-
cinated against varicella [15]. Recent varicella outbreaks in the
United States highlight the need for complete immunization
against varicella [16], and more robust reporting data are needed
to better monitor the outcomes of varicella vaccination programs
[17].
Infection with VZV produces lifelong immunity to chickenpox
through T-cell proliferative responses and B-cell induction of
anti-VZV antibodies, whereas vaccination may induce less robust
levels of neutralizing antibodies [4,18]. The true duration of immu-
nity after vaccination has not been established, and published
studies describing long-term seroprevalence of anti-VZV antibod-
ies among vaccinated persons are limited by small sample sizes
[9]. While several studies have characterized seroprevalence of
anti-VZV antibodies among various populations, there are no large
studies characterizing long-term seroprevalence in a cohort with
documented vaccine receipt compared to a cohort with docu-
mented history of chickenpox. In the context of evolving ACIP rec-
ommendations for varicella vaccination, this study analyzes a
population of young adults entering military service, comparing
those who acquired wild-type VZV infection in childhood to those
who received varicella vaccination in childhood. With estimated
varicella vaccine effectiveness and immunogenicity potentially
lower than that needed to maintain herd immunity [19,20], young
adult subpopulations unexposed to wild-type VZV may be at
increased risk for varicella outbreaks. Negative outcomes due to
chickenpox in young adults are estimated to be 2.2 times worse
than expected in the pre-vaccine era [21] and the risk of death is
25 times greater compared to children aged 1–4 years [22]. Even
in the absence of serologic evidence of immunity, vaccination typ-
ically attenuates such negative outcomes [4].
The purpose of this study is to measure the long-term sero-
prevalence of anti-VZV antibodies in a cohort of young adults
who were vaccinated against varicella in comparison to those with
a childhood history of chickenpox, and to determine risk factors for
waning seropositivity post-vaccination. The results of this study
may help characterize the effectiveness of current varicella vacci-
nation policy and may assist in the identification of non-immune
subpopulations that may be at increased risk for varicella
outbreaks.
2. Methods
2.1. Overview
A retrospective cohort study was conducted to compare the
long-term seroprevalence of anti-VZV antibodies in a cohort with
documented varicella vaccination to that of a cohort with a history
of chickenpox disease. Subgroup analyses were performed to
determine if sex, histo-blood group antigen (HBGA) expression,
or birth cohort modified the effect of this statistical relationship.
For the cohort of individuals who received varicella vaccination
without a history of chickenpox disease, waning seroimmunity
was modeled based on the time elapsed since the last vaccine dose
and other covariates which may play roles in vaccine immuno-
genicity. This model was used to estimate the duration of protec-
tive immunity conferred by the varicella vaccine using estimated
thresholds required to maintain herd immunity.
2.2. Study population and data source
Data for this study were supplied by the Health Care Informat-
ics Division of the Air Force Medical Support Agency. Data were
derived from recruits who entered US Air Force basic military
training between January 1, 2008, and December 31, 2015, and
who had documented childhood immunization records in the US
Air Force’s Aeromedical Services Information Management System
(ASIMS). ASIMS is the electronic repository for immunization data
for Military Health System beneficiaries receiving immunizations
at US Air Force military treatment facilities since 1997. Individuals
were excluded from analysis if vaccination status or vaccine
exemption status could not be ascertained, such as for those who
neither reported an exemption nor received a varicella vaccination
as recorded in ASIMS. Qualitative titer results, vaccination history,
and selected demographic and clinical data were obtained from
ASIMS. Identifiable information was removed from the datasets
prior to being released to the investigators. This study protocol
was reviewed and approved by the Office of Research at the Uni-
formed Services University.
2.3. Primary exposure
The primary exposure variables were either medical exemption
to the varicella vaccine due to a reported history of chickenpox dis-
ease or receipt of at least one varicella vaccine dose in the absence
of a medical exemption. Subjects with both reported history of
chickenpox disease and vaccine administration were classified as
having a history of disease, resulting in disease and vaccine-only
cohorts.
2.4. Primary outcome
The primary outcome of interest was the documented presence
or absence of detectible anti-VZV antibodies, as measured within
three days of starting basic military training. Serum specimens
for all subjects were processed with the BioRad BioPlex 2200
MMRV IgG multiplex flow immunoassay, which has a sensitivity
of 92.2% and specificity of 100% for the varicella component when
compared to traditional testing via enzyme immunoassay [23], and
overall agreement of 96% when compared to anticomplement
immunofluorescence tests [24]. Subjects with negative titers
received two varicella vaccine doses in accordance with standard
immunization practices. Outcomes were extrapolated from ASIMS
by either the presence of a vaccine exemption due to a positive
titer for a seropositive subject or the subsequent administration
of two varicella vaccine doses for a seronegative subject. Subjects
for whom the outcome could not be ascertained were censored
from analysis.
2.5. Potential confounders and effect modifiers
Previous studies have reported higher post-vaccination sero-
prevalence of anti-measles, mumps, rubella, and influenza anti-
bodies among women compared to men [25,26], suggesting sex
may modify the effect of seropositivity following vaccine adminis-
tration. Additionally, HBGA expression has been hypothesized to
play a role in viral and vaccine immunogenicity [27,28]. Age may
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also confound the relationship between exposure status and sero-
logic immunity in the setting of variable vaccine availability, evolv-
ing vaccination recommendations, and decreasing exposure to
wild-type VZV since the introduction of the varicella vaccine.
Therefore, data on subjects’ sex, HBGA expression, and year of birth
were included in the analysis. Furthermore, data on the number of
varicella vaccines received and the time elapsed between last vari-
cella vaccine dose and serologic outcome determination were
included in the model of waning immunity following varicella vac-
cine administration.
2.6. Statistical analysis
Descriptive epidemiological information was determined by
stratification of the two exposure types. Continuous variables were
analyzed using unpaired two sample Student’s t-tests, and categor-
ical variables were analyzed using Pearson’s chi-square tests.
Risk ratios were computed to compare the long-term sero-
prevalence following vaccine administration to that of natural
infection, and chi-square tests or Fischer exact tests with 5% two-
sided significance levels were used to determine statistical signifi-
cance, as appropriate for the covariate pattern. Effect modification
was evaluated through stratification by sex, HBGA expression, and
birth cohort. The Cochran-Mantel-Haenszel test was used to eval-
uate the presence of effect modification, and stratified results were
presented where there was heterogeneity of risk ratios across
strata.
For those in the vaccine exposure group, logistic regression was
used to evaluate long-term seroprevalence based on the time
elapsed since the last varicella vaccine dose. The dependent vari-
able for the logistic regression model was varicella seropositivity.
Independent variables included time elapsed since last vaccination
dose, year of birth, sex, HBGA expression, and number of varicella
vaccines received. Where the linearity assumption was reasonably
met, covariates were modeled as continuous variables. Multiplex
flow immunoassay-adjusted herd immunity thresholds were
derived using the methods described by Plans [29] for determining
enzyme immunoassay-based herd immunity thresholds, using the
following equation:
pc ¼ IcSe þ ½ð1 IcÞð1 SpÞ
For this equation, pc is the critical prevalence for herd immu-
nity, Ic is the accepted herd immunity threshold, Se is the sensitiv-
ity of the test, and Sp is the specificity of the test. A varicella
transmissibility factor of 7.32 was used to compute the accepted
herd immunity threshold [30]. Duration of protective immunity
following vaccine administration was estimated by comparing
model-predicted values to these threshold estimates.
For all statistical tests used, two-tailed statistical significance
was evaluated using an alpha of 0.05. Statistical analyses were per-
formed using STATA/IC v13.1 for Windows.
3. Results
3.1. Descriptive epidemiology
Of the 15,210 recruits with a childhood immunization record in
ASIMS, varicella exposure status was ascertained for 10,174
recruits (Table 1). A slight majority (52.3%) of included recruits
had a documented history of chickenpox, with the remainder hav-
ing received at least one varicella vaccination in childhood. The
mean year of birth was significantly different between these two
exposure groups (p < 0.0001), with vaccine recipients born a mean
difference of three years after those with a history of chickenpox.
The chickenpox and vaccine exposure groups were similar with
respect to sex and HBGA expression (p = 0.144 and p = 0.781,
respectively), but they were significantly different when stratified
by year of birth (p < 0.001). Sensitivity analysis was performed to
evaluate the effects of including subjects who had both history of
chickenpox and received vaccine (n = 352, 90.9% seropositive),
and all resulting descriptive statistics and measures of effect were
similar when these recruits were included in the chickenpox expo-
sure group.
3.2. Relative immunogenicity
Overall, 72.4% of vaccine recipients had a positive titer to VZV,
compared to 95.4% of those with a history of chickenpox disease
(Table 2). Among the vaccinated cohort, 46% had received only
one vaccine dose, and seroprevalence was similar regardless of
number of vaccine doses received (p = 0.0710). Varicella seroposi-
tivity was significantly lower in vaccine recipients compared to
those with a history of chickenpox (RR = 0.76 [95% CI: 0.75–
0.77]). These findings were homogeneous when stratified by sex
and HBGA expression (p = 0.2483 and p = 0.1774, respectively).
However, there was significant heterogeneity of relative immuno-
genicity when stratified by birth cohort (p < 0.0001), with varicella
vaccination being least immunogenic compared to chickenpox for
the birth cohort born after 1995 (RR = 0.69 [95% CI: 0.62–0.77]).
Because of this heterogeneity, results from this study should be
Table 1
Comparison of demographic and clinical characteristics by exposure group.
Chickenpox Vaccine Total p-valuea
Number of subjects 5323 (52.3%) 4851 (47.6%) 10,174
Year of birth, Mean (SD) 1990 (2.9) 1993 (2.8) 1991 (3.4) <0.001
Sex, n (%)
Male 4009 (75.3) 3593 (74.1) 7602 (74.7)
Female 1313 (24.7) 1258 (25.9) 2571 (25.3) 0.144
Histo-blood group antigen, n (%)
A 1742 (37.0) 1657 (36.9) 3399 (36.9)
B 583 (12.4) 535 (11.9) 1118 (12.2)
AB 168 (3.6) 174 (3.9) 342 (3.7)
O 2210 (47.0) 2127 (47.3) 4337 (47.2) 0.781
Year of birth, n (%)
<1986 165 (3.1) 45 (1.0) 211 (2.1)
1986–1990 2580 (48.5) 823 (17.0) 3403 (33.5)
1991–1995 2462 (46.2) 3085 (63.6) 5547 (54.5)
1996+ 116 (2.2) 893 (18.4) 1009 (9.9) <0.001
a Two-sample t-test for year of birth; chi-square test for sex, histo-blood group antigen, and year of birth strata.
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interpreted by birth cohort rather than using the aforementioned
pooled estimate of relative immunogenicity.
The relative immunogenicity conferred by both varicella vac-
cine and chickenpox disease declines with successive birth year,
although the decline is more precipitous with the vaccine only
cohort (Fig. 1). Varicella seroprevalence remains at or above levels
estimated to provide herd immunity among those with a history of
chickenpox disease, regardless of birth year, while seroprevalence
fails to achieve herd immunity thresholds for vaccine recipients
born after 1993.
3.3. Multivariate modeling of waning immunity
Of the 4802 recruits who received the varicella vaccine in child-
hood, 4584 (95.4%) received the varicella vaccine in accordance
with standard US practices and with at least three weeks lapsing
between vaccine administration and titer measurement. These
subjects were included in the logistic regression model of waning
immunity following varicella vaccination. Among these vaccine
recipients, seroprevalence fell below estimated levels required
for herd immunity when more than four years had elapsed since
the last varicella vaccine dose (Fig. 2).
The odds of a positive varicella titer decreased by 8% for each
successive year that elapsed since administration of the last vac-
cine dose, after adjusting for year of birth, number of vaccines
received, sex, and HBGA expression (adjusted OR = 0.92
[p < 0.001]) (Table 3). The covariate-adjusted odds of a positive
varicella titer decreased by 21% with each successive year of birth
(adjusted OR = 0.79 [p < 0.001]). Modeling the interaction between
year of birth and time elapsed since last vaccine dose did not
improve the predictive value of the model. Compared to vaccine
recipients who only received one varicella vaccine dose, the unad-
justed odds of a positive varicella titer increased when subjects
received two (OR = 1.22 [p = 0.003]) or three (OR = 2.92
[p = 0.005]) vaccine doses, but this relationship did not remain sta-
tistically significant after covariate adjustment. Sex did not signif-
icantly affect varicella seropositivity in either the crude or adjusted
models.
Among the vaccine recipients included in this model, an addi-
tional 284 subjects had unknown HBGA expression. Sensitivity
analysis was performed to evaluate the effects of excluding
subjects with missing HBGA data, and resulting adjusted measures
of effect for all variables included in the model were similar after
excluding those with missing HBGA data. Subjects with type AB
blood had 32% lower covariate-adjusted odds of a positive varicella
titer compared to those with type A blood (adjusted OR = 0.68
[p = 0.033]). There was no significant difference in the covariate-
adjusted odds of a positive varicella titer for those with type B or
type O blood compared to those with type A blood. There was no
statistically significant interaction between HBGA expression and
any of the other covariates included in this model.
4. Discussion
This study demonstrates that the varicella vaccine produces
shorter-lived seropositivity, as compared with natural infection,
and the relative seropositivity decreases with later birth cohorts.
With the declining incidence of chickenpox since the introduction
of the varicella vaccine in the United States in 1995 [2,3], the
decreasing seropositivity among younger birth cohorts may be
due to reduced natural immunity boosting from exposure to
wild-type VZV. Despite vaccination in accordance with ACIP rec-
ommendations, 15.6% of this study cohort were found to have no
serologic evidence of varicella immunity. Although serostatus
may underestimate true immunity among vaccinated individuals,
the relationship found in this study between seropositivity and
time elapsed since last varicella vaccination suggests that vacci-
nated populations previously unexposed to wild-type VZV may
be at increased risk for varicella outbreaks. Clinical and public
health personnel in these settings may benefit from access to
VZV antibody assays that can reliably predict immunity secondary
to chickenpox disease and varicella vaccination—assays which cur-
rently are not commercially available.
Among vaccine recipients with no history of chickenpox dis-
ease, year of birth and time elapsed since last vaccine dose are
the most important predictors of varicella seropositivity. Since
seroprevalence may fall below herd immunity thresholds four
years after vaccination, additional varicella booster vaccinations
may be required to maintain herd immunity in congregate settings,
such as schools and military training sites, and for women of
child-bearing age to minimize the risk of congenital varicella syn-
drome and neonatal transmission.
Table 2
Relative immunogenicity of the varicella vaccine compared to chickenpox, for the overall cohort and stratified by immunogenic variable.
Number of subjects (+) Titers to VZV Risk ratio [95% CI] p-valuea
Overall
Vaccine only (pooled) 4802 72.4% 0.76 [0.75–0.77] <0.0001
1 dose 2299 71.2% 0.75 [0.73–0.77] <0.0001
2+ doses 2505 73.5% 0.77 [0.75–0.79] <0.0001
Chickenpox 5253 95.4% 1.0 [reference] –
Total 10,055 84.4% – –
Subgroup analysis
Sex
Male 7521 84.1% 0.75 [0.74–0.77]
Female 2533 85.3% 0.77 [0.75–0.80] 0.2483
Histo-blood group antigen
A 3383 82.8% 0.76 [0.73–0.78]
B 1112 84.3% 0.76 [0.72–0.81]
AB 340 79.4% 0.67 [0.59–0.75]
O 4321 83.9% 0.74 [0.72–0.77] 0.1774
Year of birth
<1986 492 94.9% 0.84 [0.72–0.98]
1986–1990 5687 94.1% 0.91 [0.89–0.93]
1991–1995 7614 82.3% 0.78 [0.76–0.80]
1996+ 1236 57.6% 0.69 [0.62–0.77] <0.0001
a Chi-square test for overall cohort, Mantel-Haenszel test for homogeneity when stratified by subgroup.
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While sex has been previously reported to modify the effects of
influenza vaccine immunogenicity [26], sex was not shown in this
study to affect either the relative immunogenicity of the varicella
vaccine or the duration of seropositivity following varicella vaccine
administration. Histo-blood group antigens are thought to affect
vaccine and viral immunogenicity, especially among enteric patho-
gens [27,28,31–33], and the relationship between HBGAs and
immunogenicity to varicella vaccine has not been previously
described. The significant association identified in this study may
warrant further research.
4.1. Strengths and limitations
The most significant strengths of this study were the large
cohort size permitting subgroup analyses and the database’s longi-
tudinal nature with accurate serologic outcomes. Additionally, this
study has good internal validity as the study cohort is composed of
former military dependents, of similar socioeconomic status with
assured access to reliable medical care. The only significant
difference between the vaccinated and disease exposure groups
was their year of birth. As a condition of entry into military service,
all members of this cohort are free of immunocompromising con-
ditions at the time of serologic outcome determination. In addition,
this large cohort of young adult military recruits is sufficiently
diverse to be generalizable to other US populations.
This study also has several limitations. First, given the sensitiv-
ity of the immunoassay used to assess serostatus, some false neg-
atives were likely. Outcome misclassification would be non-
differential with respect to exposure status, however, thus biasing
results toward the null. While herd immunity threshold estimates
were adjusted for the test characteristics of the assay [29], further
studies are needed to assess the longevity of anti-VZV antibodies
post-vaccination using more sensitive measures of seroimmunity.
Second, since dates of chickenpox disease were unknown, the data-
set did not permit characterization of waning immunity following
a history of disease. Third, although the study incorporated several
important covariates, other variables that may influence vaccine
immunogenicity (e.g., genetic factors [34,35]) were unavailable.
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Fourth, this study relied on parental report for history of chicken-
pox disease; verification was infeasible. Finally, this study relied on
measures of humoral immunity, which may less reliably predict
disease risk than measures of cell-mediated immunity [36–38].
However, serologic evidence of immunity is the international stan-
dard by which vaccine immunogenicity is currently measured [37–
41], and although seronegativity and disease susceptibility are not
identical, loss of detectible antibody is associated with an
increased risk of breakthrough disease [42].
5. Conclusion
This study was conducted in a large population of US adults
who have accessible, accurate electronic childhood immunization
records, and who had varicella titers drawn in early adulthood.
Seroprevalence as measured by multiplex flow immunoassay in
the cohort of study subjects born after implementation of the US
varicella vaccination program in 1995 is below the threshold esti-
mated to provide herd immunity. Additional studies which reliably
measure long-term immune response to vaccination are needed. If
vaccination in accordance with the current US VZV vaccination
schedule is inadequate to maintain herd immunity, young adults
not previously exposed to wild-type VZV may be at increased risk
for varicella outbreaks.
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